

**Amendments to the Specification**

Please replace paragraph [0005] with the following paragraph:

[0005] A number of variant forms of IGF-I have been created which have altered binding characteristics for the IGF receptors, the insulin receptor, or IGFBP's (e.g., [Ser24] IGF-I (Cascieri *et al.* (1988) *Biochemistry* 27:3229-3233 and (1989) *J. Biol. Chem.* 264:2199-2202); [Ala31, Leu60] IGF-I, [Leu24, Leu60] IGF-I, and [Leu24, Ala31, Leu60] IGF-I (Bayne *et al.* (1990) *J. Biol. Chem.* 265:15648-15652); [1-27, Gly4, 38-70] IGF-I, and [Leu24, 1-62] IGF-I (Baxter *et al.* (1992) *J. Biol. Chem.* 267:60-65)). Additionally, International Patent Application No. WO 97/39032 discloses the use of certain variant forms of IGF-I for the treatment of conditions where increased IGF-I activity is desired, such as diabetes, osteoporosis, and the like. The variant forms of IGF-I are proposed to displace IGF-I from IGFBP, resulting in increased IGF-I activity.